Guardant Health Partners with Cancer Research UK to Advance Cancer Detection

Published Mar. 01, 2024

By Hopkins Medtech

December 4th, Guardant Health announced its collaboration with Cancer Research UK to collaborate on technology, data, and research aimed at advancing cancer detection and treatment.

 

The collaboration will primarily focus on clinical trials conducted by Cancer Research UK’s Drug Development Center, including the first national precision medicine clinical trial for rare cancers conducted in the UK, named DETERMINE.

 

By sharing data and samples from Cancer Research UK-funded research networks, Guardant can further develop and validate its liquid biopsy and tumor tissue sequencing technologies.

 

The DETERMINE trial is sponsored and managed by Cancer Research UK’s Drug Development Center. Led by the University of Manchester in partnership with the University of Birmingham, the Royal Marsden NHS Foundation Trust, and the Christie NHS Foundation Trust, this study is expected to recruit adult and pediatric patients, span five years, and include a two-year follow-up.

 

According to GlobalData’s Clinical Trials Database, the number of oncology trials in the UK has steadily increased over the past decade. Cancer trials in the UK have consistently represented a quarter of all clinical trial activities in the country over the last ten years.

 

Guardant Health is a globally leading precision oncology company, focusing on helping combat cancer worldwide by employing its proprietary tests, vast datasets, and advanced analytics. The Guardant Health Oncology Platform leverages comprehensive resources to drive commercial adoption, improve patient clinical outcomes, and reduce healthcare costs across the cancer care continuum. Guardant Health has commercialized Guardant360®, Guardant360 CDx, Guardant360 TissueNext, Guardant360Response, and GuardantOMNI tests for advanced cancer patients, along with Guardant Reveal™ for early-stage cancer patients. Their screening product portfolio, including the commercially launched Shield test, aims to meet the needs of individuals eligible for cancer screening.

 

Guardant Health announced its 2023 Q3 financial report earlier last month, with a revenue of $143 million for the quarter, marking a 22% increase from $117 million in 2022. The revenue for the first three quarters of this year reached $409 million, a 27% increase year-over-year. In Q3 this year, precision oncology revenue increased from $102 million in the same period last year to $133 million, driven mainly by an increase in clinical testing and biopharma sample volumes, growing by 35% and 11% respectively compared to the previous year. Guardant reported conducting 43,900 tests for clinical customers and 7,500 tests for biopharma customers in Q3 this year.